NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Anavex Life Sciences Corp. (AVXL) Stock Analysis

Anavex Life Sciences Corp. (AVXL) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

AVXL

$1.36

$0.00 (0.00%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AVXL with… →

AVXL Key Statistics

As of Oct 21, 2026
Trading
Open
$1.40
Previous Close
$1.36
Day's Range
1.31–1.40
52-Week Range
1.14–9.50
Volume
1.05M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.17
Valuation
Market Cap
$126.07M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.14
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$46.38M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
92.70M
1-Year Return
−85.45%
Dividend and dates
Earnings Date
November 24, 2026estimated
Avg Volume
1.04M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, AVXL closed at $1.36, −85.45% over 1 year.

Anavex Life Sciences Corp. (AVXL) has a market capitalization of $126.07M.

In fiscal 2025, AVXL reported revenue of $0.00.

AVXL Stock Return by Calendar Year

Anavex Life Sciences Corp. (AVXL) 10-year return: what $10,000 became

1 year
$10,000 $1,455
−85.45%
5 years
$10,000 $756
−92.44%
10 years
$10,000 $4,084
−59.16%

If you had invested $10,000 in Anavex Life Sciences Corp. (AVXL) 10 years ago, at the close on October 21, 2016, it would have been worth $4,084 at the close on October 21, 2026: −59.16% in total, −8.57% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−61.80%
2025−66.85%
2024+15.36%
2023+0.54%
2022−46.60%
2021+221.11%
2020+108.49%
2019+66.03%
2018−51.55%
2017−18.69%
2016 (partial year)+24.92%

As of October 21, 2026.

AVXL Revenue and Earnings by Fiscal Year

FY ends September
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$46.38M—
2024$0.00−$43.00M—
2023$0.00−$47.51M—
2022$0.00−$47.98M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$51.37M−$46.38M—
2024$0.00—−$52.80M−$43.00M—
2023$0.00—−$55.74M−$47.51M—
2022$0.00—−$50.99M−$47.98M—

Annual figures as reported, in the company's reporting currency. As of September 30, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Anavex Life Sciences Corp. (AVXL) at $126.07M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 34.

AVXL last closed at $1.36 on October 21, 2026. The close was unchanged from the previous session. The 52-week range on file runs from $1.14 to $9.50. The latest close sits 19.3% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $46.38M. Earnings per share on a trailing basis come to −0.14.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the total return is −85.45%. Across 10 years the annualized return works out at −8.57%. The reported beta is 1.17. Daily returns over the trailing 10 years annualize to a volatility of 82.76%.

Growth & Income

The record shows no dividend for AVXL.

Across the complete calendar years on file, 2021 returned +221.11% and 2025 returned −66.85%. Of the 9 complete calendar years on file, 5 finished higher. So far in 2026 the total return is −61.80%.

Peer Comparison

Anavex Life Sciences Corp. (AVXL) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Anavex Life Sciences Corp. AVXL $126.07M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Anavex Life Sciences Corp. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, as well as exhibits anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71 that targets SIGMAR1 and M1 muscarinic receptors, which is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, such as cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.

Visit website →